SUPN - ス―パ―ナス・ファ―マス―ティカルズ (Supernus Pharmaceuticals Inc.)

SUPNのニュース

   Supernus Pharma appoints Opgen executive as new CFO  2021/07/30 15:49:20 Seeking Alpha
   Supernus Pharma inks supply agreement with Bachem for key ingredient in ADHD drug  2021/07/20 10:48:19 Seeking Alpha
   Thinking about buying stock in Fisker, Torchlight Energy, Intec Pharma, Supernus Pharmaceuticals, or Cyclo Therapeutics?  2021/06/17 13:31:00 Benzinga
NEW YORK , June 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FSR, TRCH, NTEC, SUPN, and CYTH. Full story available on Benzinga.com
   Apomorphine Hydrochloride Market Risk Factors, Economic Fluctuations, Drivers In Future Analysis By -2027|Supernus Pharmaceuticals, Britannia Pharmaceuticals STADA, Ever Pharma  2021/06/13 16:17:50 Jumbo News
The global Apomorphine Hydrochloride market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future status of the global Apomorphine Hydrochloride market. The research study comes out as a compilation []
   Supernus Pharmaceuticals Stock Getting Closer To Key Technical Measure  2021/06/10 17:21:00 Investor''s Business Daily
A Relative Strength Rating upgrade for Supernus Pharmaceuticals shows improving technical performance. Will it continue?
   Thinking about buying stock in Fisker, Torchlight Energy, Intec Pharma, Supernus Pharmaceuticals, or Cyclo Therapeutics?  2021/06/17 13:31:00 Benzinga
NEW YORK , June 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FSR, TRCH, NTEC, SUPN, and CYTH. Full story available on Benzinga.com
   Apomorphine Hydrochloride Market Risk Factors, Economic Fluctuations, Drivers In Future Analysis By -2027|Supernus Pharmaceuticals, Britannia Pharmaceuticals STADA, Ever Pharma  2021/06/13 16:17:50 Jumbo News
The global Apomorphine Hydrochloride market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future status of the global Apomorphine Hydrochloride market. The research study comes out as a compilation []
   Supernus Pharmaceuticals Stock Getting Closer To Key Technical Measure  2021/06/10 17:21:00 Investor''s Business Daily
A Relative Strength Rating upgrade for Supernus Pharmaceuticals shows improving technical performance. Will it continue?
   Analysts Top Healthcare Picks: Novavax (NVAX), Supernus Pharmaceuticals (SUPN)  2021/06/02 12:25:40 Smarter Analyst
Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Novavax (NVAX), Supernus Pharmaceuticals (SUPN) The post Analysts Top Healthcare Picks: Novavax (NVAX), Supernus Pharmaceuticals (SUPN) appeared first on Smarter Analyst .
   Aequus Pharmaceuticals bringing diverse pipeline of new drugs to the Canadian market  2021/05/28 21:00:00 Proactive Investors Canada
Focused on developing and commercializing high-quality products Pipeline includes several commercial products in ophthalmology and transplant Also has a development stage pipeline in neurology What Aequus Pharmaceuticals does Aequus Pharmaceuticals Inc (CVE:AQS) (OTCQB:AQSZF) is a specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. The Vancouver-based company takes medications that are already available in the US or elsewhere and licenses or acquires the Canadian rights, then takes the clinical data that supported that approval and works with Health Canada, Canadas national health system, to get them approved and commercialized in Canada. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established medicines and looks to form strategic partnerships that would maximize the reach of its product candidates worldwide. The company has expanded its pipeline to include several commercial products in Opthalmology and transplant and also has a development stage pipeline in neurology with the goal of addressing a need for improved medication adherence through enhanced delivery systems.
   Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates  2021/05/01 15:43:34 Benzinga
Following a mixed month in April, the Food and Drug Administration sets out to review another slate of drugs in May. ACADIA Pharmaceuticals Inc.'s (NASDAQ: ACAD ) Nuplazid failed to get label expansion to include the indication of dementia-related psychosis. The FDA did not keep its tryst with the decision dates for ACADIA Pharmaceuticals Inc.'s (NASDAQ: ACAD ) pain drug and Sol-Gel Technologies Ltd.'s (NASDAQ: SLGL ) investigational skin inflammation treatment. Protalix BioTherapeutics, Inc.'s (NASDAQ: PLX ) Fabry disease treatment candidate also faced rejection at the FDA altar. The regulatory agency extended the review period for Pfizer Inc.'s (NYSE: PFE ) atopic dermatitis drug. On the other hand, Supernus Pharmaceuticals, Inc.'s (NASDAQ: SUPN ) attention deficit hyperactivity drug cleared the FDA hurdle in its second attempt. And GlaxoSmithKline plc's (NYSE: GSK ) Jemperli, a new molecular entity, won the nod for advanced endometrial cancer. Another the NMEs approved during the month was ADC Therapeutics SA's (NYSE: ADCT ) Zynlonta in relapsed or refractory large B-cell lymphoma.
   The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split  2021/04/15 11:49:24 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14) 10x Genomics, Inc. (NASDAQ: TXG ) Affimed N.V. (NASDAQ: AFMD ) Bio-Techne Corporation (NASDAQ: TECH ) - announced out-licensing of antibody treatment candidate to Xencor, Inc. (NASDAQ: XNCR ) BioNTech SE (NASDAQ: BNTX ) - reacted to increased EU orders for its COVID-19 vaccine in the wake of the Johnson & Johnson (NYSE: JNJ ) setback Globus Medical, Inc. (NYSE: GMED ) Medpace Holdings, Inc. (NASDAQ: MEDP ) Medtronic plc (NYSE: MDT ) Merit Medical Systems, Inc. (NASDAQ: MMSI ) Natus Medical Incorporated (NASDAQ: NTUS ) NuVasive, Inc. (NASDAQ: NUVA ) PLx Pharma Inc. (NASDAQ: PLXP ) PPD, Inc. (NASDAQ: PPD ) - moved on rumors of a potential buyout by Thermo Fisher Scientific Inc. (NYSE: TMO ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN ) Zimmer Biomet Holdings, Inc. (NYSE: ZBH ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 14) Bellerophon Therapeutics, Inc. (NASDAQ: BLPH ) Celyad Oncology SA (NASDAQ: CYAD ) Design Therapeutics, Inc. (NASDAQ: DSGN ) Kronos Bio, Inc. (NASDAQ: KRON ) Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT ) Metacrine, Inc. (NASDAQ: MTCR ) Millendo Therapeutics, Inc. (NASDAQ: MLND ) Nabriva Therapeutics plc (NASDAQ: NBRV ) Osmotica Pharmaceuticals plc (NASDAQ: OSMT ) Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) Titan Pharmaceuticals, Inc. (NASDAQ: TTNP ) Stocks In Focus Regenxbio Doses First Patient In Gene Therapy Study REGENXBIO Inc. (Nasdaq: RGNX ) said it dosed the first patient in Cohort 3 of the ongoing Phase I/2 trial of RGX-121 for the treatment of Mucopolysaccharidosis Type II, also known as Hunter Syndrome, in patients up to five years old.
   Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates  2021/04/02 12:00:21 Benzinga
A slew of drugs, including four new molecular entities, were approved in the month of March. NMEs are drugs that contain active moieties that have never been approved by the Food and Drug Administration previously and are indicators of innovation in drug research. Among the notable approvals that came through in the month were Abecma, the first-ever cell therapy for a type of blood cancer; Fotivda, AVEO Pharmaceuticals, Inc.'s (NASDAQ: AVEO ) oral, next-generation therapy for treating advanced renal cell carcinoma; and KemPharm, Inc.'s (NASDAQ: KMPH ) Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder in patients age six years and older. PDUFA dates are binary events that invariably serve as make-or-break catalysts for stocks. These dates are deadlines by which the FDA reviews a new drug application before announcing its decision concerning the approvability/non-approvability of the drug. Here are the key FDA approvals scheduled for April. Acadia Hopes Against Hope to Get Label Expansion Psychosis Drug Company: ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Type of Application: supplemental new drug application Candidate: pimavanserin Indication: dementia Date: April 3 Pimavanserin, which is marketed under the trade name Nuplazid, has already been approved by the FDA for the treatment of hallucinations associated with Parkinson's disease psychosis.
   Supernus Pharmaceuticals (SUPN) Set to Announce Quarterly Earnings on Thursday  2021/02/24 15:17:13 Transcript Daily
Supernus Pharmaceuticals (NASDAQ:SUPN) is scheduled to be announcing its earnings results after the market closes on Thursday, February 25th. Analysts expect the company to announce earnings of $0.57 per share for the quarter. Shares of Supernus Pharmaceuticals stock opened at $29.58 on Wednesday. Supernus Pharmaceuticals has a 52-week low of $13.12 and a 52-week high […]
   The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts  2021/02/11 12:26:22 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X Genomics Inc (NASDAQ: TXG ) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Abbott Laboratories (NYSE: ABT ) Acasti Pharma Inc (NASDAQ: ACST ) (reacted to its quarterly results) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alimera Sciences Inc (NASDAQ: ALIM ) Alkermes Plc (NASDAQ: ALKS ) Allakos Inc (NASDAQ: ALLK ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Apyx Medical Corp (NASDAQ: APYX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Artelo Biosciences Inc (NASDAQ: ARTL ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) AtriCure Inc. (NASDAQ: ATRC ) Avanos Medical Inc (NYSE: AVNS ) Beigene Ltd (NASDAQ: BGNE ) Bio-Path Holdings Inc (NASDAQ: BPTH ) (announced receipt of third patent related to manufacture of platform technology) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cancer Genetics Inc (NASDAQ: CGIX ) (reacted to an update to merger terms with StemoniX) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Clearside Biomedical Inc (NASDAQ: CLSD ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) Edap Tms SA (NASDAQ: EDAP ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Gamida Cell Ltd (NASDAQ: GMDA ) ( reacted to a positive late-stags readout) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Ideaya Biosciences Inc (NASDAQ: IDYA ) Illumina, Inc.

calendar